For the Inventor, By the Inventor

Enter assignee name

Irving, TX, United States of America

Reata Pharmaceuticals, Inc.

USPTO Granted Patents = 63

% Expired Patents = 3.2

CIPO Patents = 6

EPO Patents = 21

Trademarks = 6

Forward Citations = 1,414

Loading Chart...

Loading Chart...

44 inventors (with patents filed for the assignee):

Xin Jiang (49 out of 57 patents)

Melean Visnick (48 out of 50 patents)

Eric Anderson (29 out of 47 patents)

4. Christopher F Bender (18 out of 18 patents)

5. Gary Louis Bolton (17 out of 31 patents)

6. Chitase Lee (14 out of 24 patents)

7. Xiaofeng Liu (14 out of 15 patents)

8. Bradley W Caprathe (14 out of 32 patents)

9. Robert M Kral, Jr (10 out of 10 patents)

10. William Howard Roark (8 out of 25 patents)

11. Colin J Meyer (7 out of 9 patents)

12. John Allen Walling (5 out of 5 patents)

13. Martha R Hotema (5 out of 5 patents)

14. Jack Greiner (5 out of 5 patents)

15. Stephen S Szucs (5 out of 7 patents)

Core Competencies:

Antioxidant

Inflammation

Modulators

Triterpenoids

Oleanolic Acid

ROR-gamma

IL-17

Bardoxolone

Cysteine-dependent

Sugar Groups

Natural Products

Synthetic Derivatives

63 patents: Sort by Forward Citations

1. 12595278 - BIARYL AMIDES WITH MODIFIED SUGAR GROUPS FOR TREATMENT OF DISEASES ASSOCIATED WITH HEAT SHOCK PROTEIN PATHWAY (2026-04-07),

2. 12545701 - C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses (2026-02-10),

3. 12344631 - C17 polar-substituted heteroaromatic synthetic triterpenoids and methods of use thereof (2025-07-01),

4. 12195443 - Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses (2025-01-14),

5. 12060340 - Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith (2024-08-13),

6. 11993574 - Pyrazole and imidazole compounds for inhibition of IL-17 and RORgamma (2024-05-28),

7. 11827664 - Biaryl amides with modified sugar groups for treatment of diseases associated with heat shock protein pathway (2023-11-28),

8. 11814338 - Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (2023-11-14),

9. 11584775 - C4-modified oleanolic acid derivatives for inhibition of IL-17 and other uses (2023-02-21),

10. 11406648 - C17-heteroaryl derivatives of oleanolic acid and methods of use thereof (2022-08-09),

11. 11401294 - Co-crystal forms of a novobiocin analog and proline (2022-08-02),

12. 11292781 - Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses (2022-04-05),

13. 11192852 - Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators (2021-12-07),

14. 11091430 - Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17 (2021-08-17),

15. 11078230 - 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof (2021-08-03),

Reata Pharmaceuticals, Inc. is a biopharmaceutical company based in Irving, Texas, specializing in the development of innovative therapies targeting oxidative stress and inflammation. The company focuses on antioxidant inflammation modulators, particularly in the realm of triterpenoids, with compounds such as oleanolic acid playing a significant role in their research. Reata's work is centered around addressing conditions linked to ROR-gamma and IL-17 pathways, aiming to improve patient outcomes through advanced therapeutic solutions.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Reata Pharmaceuticals, Inc.

63 Patents

#7 in Irving, TX

#316 in Texas

#5,756 in US

#11,617 in the World

Irving, TX, United States of America

Reata Pharmaceuticals, Inc.

Forward Citations = 1,414

44 inventors:

Xin Jiang (49 out of 57 patents)

Melean Visnick (48 out of 50 patents)

Eric Anderson (29 out of 47 patents)

4. Christopher F Bender (18 out of 18 patents)

5. Gary Louis Bolton (17 out of 31 patents)

Please report any incorrect information to [email protected]

Loading…